Boston Scientific Was Already Breaking Before The Cyberattack

Boston Scientific went from $105.65 in November to about $43.55 this month. That is roughly a 59% collapse.

Then the CEO stepped in and bought $9 million of his own company’s stock.

Michael Mahoney bought 186,240 shares on August 3 at an average of $48.33. SEC filings show it was an actual open-market purchase, not an option exercise or automatic compensation transaction. Director David Habiger also bought shares around the same time.

At first glance, that looks like the classic insider-confidence signal.

But look at the timing.

Boston Scientific was already in trouble before the cyberattack became the headline.

In the first quarter, sales were still growing 9.4% organically. That sounds fine until you look underneath it. WATCHMAN, one of the company’s important growth products, grew 18.8%, but Boston Scientific admitted the growth was below expectations and that U.S. procedure volumes were weakening as the quarter progressed. The company also reported increased competition in electrophysiology.

Then the problem got worse.

By July, management cut its 2026 earnings outlook to $3.28–$3.32 per share from $3.34–$3.41.

The reason wasn’t mysterious.

WATCHMAN demand was softer than expected, while competition in U.S. electrophysiology was causing market-share losses. CEO Michael Mahoney told analysts that the second half of the year would be more pressured than previously expected.

And Boston Scientific simultaneously announced a $700–$800 million restructuring program.

The company plans to move production between factories, reorganize parts of the business and change its supply chain. It expects about $500 million of annual expense reductions once the program is fully implemented. The changes are expected to run through 2029.

That is not what a company does because everything is going perfectly.

Then came the cyberattack.

Boston Scientific disclosed on August 25 that unauthorized activity had disrupted access to operating systems and business applications. Manufacturing, order processing and shipments were affected. By September, the company said it was unlikely to meet its previously issued third-quarter and full-year 2026 sales and adjusted-profit forecasts.

Now look at the sequence.

Growth disappoints.

WATCHMAN slows.

Competition takes share.

Guidance gets cut.

Management announces a $700–$800 million restructuring.

CEO buys $9 million of stock.

Then the cyberattack hits an already weakened operating system.

That makes the insider purchase much harder to interpret than the usual “the CEO knows something” story.

Mahoney may genuinely believe the market has overreacted. He may be right.

But the purchase does not erase the operating problems that existed before he bought the shares.

And there is another detail worth watching.

The restructuring is supposed to save roughly $500 million a year, but the company expects to spend up to $800 million to get there, with most of the work stretching through 2029.

So investors aren’t simply betting on whether Boston Scientific’s products are good.

They are betting that management can repair a business whose growth engine has started losing momentum, regain ground in electrophysiology, get WATCHMAN growing again, absorb a major cyber disruption, and execute a multiyear restructuring at the same time.

That is a very different bet from “this stock is down 60%, therefore it is cheap.”

And the market has already given us one useful test.

Mahoney bought around $48.33.

The stock subsequently fell into the low $40s.

Insider buying can tell you what one person believes the company is worth. It cannot tell you when the market will agree.

Boston Scientific may eventually prove Mahoney right.

But if you’re trying to understand why this stock collapsed, the cyberattack is only the latest chapter.

The deterioration was already visible in the numbers before the hackers ever showed up.

Not financial advice.